Navigation Links
Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
Date:10/30/2010

BOSTON, Oct. 30 /PRNewswire/ -- Tibotec Pharmaceuticals (Tibotec) announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.  

The results showed that in the four TMC435 treatment groups between 79 and 86 percent of patients were able to stop all therapy at Week-24, according to the response criteria defined in the study protocol. There were no relevant differences for adverse events between TMC435 treatment groups and placebo. TMC435, a hepatitis C protease inhibitor, dosed once daily (q.d.) is being developed jointly by Tibotec Pharmaceuticals and Medivir.

The PILLAR study [Protease Inhibitor TMC435 trial assessing the optimaL dose and duration as once daiLy Anti-viral Regimen] (TMC435-C205; NCT00882908) is an ongoing, five-arm, global phase 2b randomized, double-blind, placebo controlled study in 386 treatment-naive patients. TMC435 was administered in doses of 75mg or 150mg q.d. for either 12 weeks or 24 weeks in combination with 24 weeks of peg-interferon and ribavirin (PR). Patients in the placebo arm receive 24 weeks of placebo plus peg-interferon and ribavirin followed by 24 additional weeks of peg-interferon and ribavirin treatment. The primary endpoint of the study is sustained virologic response at Week-72 (SVR24). The PILLAR study is being conducted in 13 countries in Europe, North America, and Australasia.

Patients receiving TMC435 were allowed to stop all treatment at week 24 when a) HCV RNA levels < 25 IU/mL at week 4  and b) HCV RNA < 25 IU/mL levels at weeks 12, 16 and 20. Patients who did not meet the above resp
'/>"/>

SOURCE Tibotec Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
4. LPBP Inc. - Re-filing certification of interim filings
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. Arpida Reports Interim Results for Six Months to 30 June 2008
7. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
8. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
9. Misonix Announces Interim Distribution Agreement for Italy
10. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
11. Interim Analysis of Data from e-HEALING Registry of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented at AHA Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... N.H. , May 22, 2013  Superior ... the Year 2013" by Business NH Magazine.  For ... Granite State organizations that distinguish themselves with extraordinary ... very proud to receive this honor," said ... Controls.  "As with any recognition, this award is ...
(Date:5/22/2013)... May 22, 2013 Genedata, a ... biotechnology, drug discovery, and life science research, today ... ™ as its bioinformatics platform for strain ... Genedata will provide AB Enzymes, one of the ... hosted solution of Genedata Selector accompanied by bioinformatics ...
(Date:5/22/2013)... AudioNotch is the ... treatment. AudioNotch is pleased to announce a partnership ... in both British Columbia and Alberta, Destination Hearing ... services. AudioNotch's tinnitus treatment program is now available ... Destination Hearing clinic, patients have the detection of ...
(Date:5/22/2013)... 2013 Express Diagnostics Int’l, Inc. ... are pleased to announce a sponsorship agreement with ... New Zealand distributor of DrugCheck® onsite testing devices, manufactured ... in the Austin 400 May 17-19 in Austin, Texas. ... that involves each car of the Erebus Motorsport team ...
Breaking Biology Technology:Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 2AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 3AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization 4AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2
... July 12 /PRNewswire/ - Ocean Nutrition Canada (ONC) supplier ... supplement ingredients, announces today the acquisition of the exclusive global marketing ... , , , ... result of the agreement, ONC acquired the rights to exclusive use ...
... , July 12 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE ... international,biopharmaceutical company with operations in the U.S. and ... $700,000 contract from the U.S. Army,Medical Research ... under U.S. Army Medical Research Acquisition,Activity contract number: (W81XWH-10-2-0039). ...
... REYKJAVIK, Iceland , July 12, 2010 Points ... and Early Detection of Abdominal Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at ... countries across Europe and North America today,report the ...
Cached Biology Technology:Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 2Ocean Nutrition Canada Announces Acquisition of Exclusive License to GAT Food Essentials, Omega-3 Microencapsulation-Emulsion Technology 3NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds 2NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds 3NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds 4NeoStem to Receive $700,000 from the U.S. Army's Medical Research and Materiel Command to Advance Adult Stem Cell Therapies in Treating Traumatic Wounds 5deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4
(Date:5/21/2013)... , Where? Copenhagen, Denmark: Bella Center ... 2013 , Why? An annual ... policy developments, manufacturing and installation, drawing on leading experiences ... 2013 edition from a record of more than 900 ... 240 plenary and oral presentations, more than 460 visual ...
(Date:5/21/2013)... which alter the way genes function without changing ... in the blood of pregnant women during any ... depression in the weeks after giving birth, and ... , The findings of the small study involving ... journal Molecular Psychiatry . , "Postpartum depression ...
(Date:5/20/2013)... known about the effect of physical education (PE) on ... finds that increasing the amount of time that elementary ... obesity. , The study represents some of the first ... obesity, and is forthcoming in the Journal of ... the study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
... by Chongsuk Ryou, researcher at the UK Sanders-Brown ... and molecular genetics in the UK College of ... prion diseases. Prion diseases, which include Creutzfeldt-Jakob ... cow" disease) in cattle, are caused by prions ...
... through the process of photosynthesis, using sunlight to produce sugars. ... transport of sugars to build different parts of the plant. ... million grant from the National Science Foundation to lead a ... of carbohydrates in corn. This research may lead to ...
... Sex and violence, or at least death, are the key to ... der Niet at the University of KwaZulu-Natal shows that the orchid ... flesh. A new study comparing the scent of the orchids with ... of Botany http://dx.doi.org10.1093/aob/mcr048 . The orchid S. ...
Cached Biology News:MU researcher leads new $6.6 million study that could lead to better corn plants 2Orchid wears the scent of death 2
... StabilCoat Plus Microsphere/Microarray Stabilizer is an aqueous ... and other non-toxic chemicals in a PBS ... 7.4. This product contains a combination ... a preservative. StabilCoat Plus Stabilizer provides ...
... The Corning CellBIND surface is produced by ... more hydrophilic surface giving more consistent, even ... CellBIND enhances cell attachment and growth uunder ... medium. • CellBIND may provide a more ...
... clone K28/86.2, PDZ Domain GenBank ... : GST fusion to residues 77-299 ... Tris pH 7.4, 0.075M NaCl containing ... evaluated by immunoblot on rat brain ...
... acquisition, analysis and experiment control software. ... with on-line and off-line analysis. powerful ... script language allowing the user to ... requirements. Applications range from basic data ...
Biology Products: